ResultsIQ

ResultsIQ › Latest results › Yatharth Hospital & Trauma Care Services Limited

Yatharth Hospital & Trauma Care Services Limited Q2 FY26 results deck summary

NSE: YATHARTH · BSE: 543950

Results deck of 13 Nov 2025, summarised by AI from the filing.

Q2 FY26 revenue ₹2,794 mn (+28% YoY) and PAT ₹413 mn (+33% YoY); Agra hospital to be integrated in H2 FY26.

Key takeaways

  1. Margin drag Profitability margin drag from losses in newer hospitals and Super Speciality Centres of Excellence.

Original filing on BSE

Yatharth Hospital & Trauma Care Services Limited Q1 FY27 results

As filed: Revenue ₹393 cr (+52% year on year), EBITDA ₹91.7 cr (+41% year on year), PAT ₹45.4 cr (+8% year on year), EBITDA margin 23.4% (−184 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹342 cr (+47% year on year), EBITDA ₹79.9 cr (+38% year on year), PAT ₹44.7 cr (+15% year on year), EBITDA margin 23.4% (−160 bps). Score 69 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was below it. EBITDA margin fell 160 bps year on year. Tax rate 14%. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Revenue rose ₹110 cr on a year ago, more than the ₹54.0 cr it added the year before. Share price after the results: −0.6% in 30 days (Nifty 500: +2.1%).
  • Q3 FY26: Revenue ₹320 cr (+46% year on year), EBITDA ₹74.3 cr (+35% year on year), PAT ₹43.1 cr (+44% year on year), EBITDA margin 23.2% (−195 bps). Score 88 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was above it. EBITDA margin fell 195 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +3.6% in 29 days (Nifty 500: −4.5%).
  • Q2 FY26: Revenue ₹279 cr (+28% year on year), EBITDA ₹65.0 cr (+18% year on year), PAT ₹41.0 cr (+32% year on year), EBITDA margin 23.3% (−193 bps). Score 64 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit growth was above it. EBITDA margin fell 193 bps year on year. Revenue rose ₹61.0 cr on a year ago, more than the ₹47.0 cr it added the year before. Share price after the results: −5.3% in 29 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹258 cr (+22% year on year), EBITDA ₹65.0 cr (+23% year on year), PAT ₹42.0 cr (+40% year on year), EBITDA margin 25.2% (+19 bps). Score 57 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was in line with it; profit growth was above it. EBITDA margin rose 19 bps year on year. Revenue rose ₹46.0 cr on a year ago, against ₹57.0 cr the year before. Share price after the results: +18.1% in 30 days (Nifty 500: −0.2%).
  • Q4 FY25: Revenue ₹232 cr (+30% year on year), EBITDA ₹58.0 cr (+26% year on year), PAT ₹39.0 cr (+3% year on year), EBITDA margin 25.0% (−84 bps). Score 61 of 100, In line with trend. EBITDA margin fell 84 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +0.7% in 30 days (Nifty 500: +2.3%).
  • Q3 FY25: Revenue ₹219 cr (+31% year on year), EBITDA ₹55.0 cr (+17% year on year), PAT ₹30.0 cr (+3% year on year), EBITDA margin 25.1% (−303 bps). Score 55 of 100, In line with trend. EBITDA margin fell 303 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 3% from last quarter.
  • Q2 FY25: Revenue ₹218 cr (+27% year on year), EBITDA ₹55.0 cr (+20% year on year), PAT ₹31.0 cr (+11% year on year), EBITDA margin 25.2% (−167 bps). Score 59 of 100, In line with trend. EBITDA margin fell 167 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Yatharth Hospital & Trauma Care Services Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.